Press Releases

Novan’s Nitric Oxide Drug Candidate Inhibits Growth of Papillomavirus in Translational Animal Model

September 8, 2014

DURHAM, N.C. - Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced today that Novan’s nitric oxide drug candidate SB206 was shown to inhibit papilloma growth in a preclinical animal study. 

Full Story

Novan’s Nitricil™ Technology Shows Efficacy Against Multidrug Resistant Superbugs

August 19, 2014

DURHAM, N.C. - Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced today that the Company’s Nitricil™ platform technology has been shown to be efficacious against several of the most multi-drug resistant pathogens plaguing civilian and military health care providers across the globe.

Full Story

Novan to Present Antiviral Preclinical Results of Nitric Oxide-Releasing Drug Candidates for the Treatment of Papillomavirus

August 14, 2014

DURHAM, N.C. - Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, announced today that antiviral data from a preclinical animal study has been accepted for presentation at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 5-9, 2014, in Washington, DC. 

Full Story

Novan Therapeutics' Pipeline Fueled by Public-Private Partnerships Receives National Recognition

June 19, 2014

DURHAM, N.C. - Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced today that the U.S. Small Business Administration recently named the Company a 2014 Tibbetts Award winner. 

Full Story

Close
Close